PMPascal Melin

Pascal Melin

*This is an algorithmically generated author record based on publicly available information.

Pascal Melin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Philippe Lang

    Department of Psychiatry and Addiction, Hospital of Erstein, Erstein, France

    3 shared publications
  • Michel Chousterman

    Department of Hepato‐Gastroentrology, Hospital of Créteil (CHIC), Créteil, France

    2 shared publications
  • Michel Rotily

    Department of Epidemiology and Public Health, ClinSearch, Bagneux, France

    2 shared publications
  • Patrice Cacoub

    Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France

    2 shared publications
  • Thierry Fontanges

    Department of Hepato‐Gastroenterology, General Hospital of Bourgoin, Bourgoin Jailleu, France

    2 shared publications
  • Claire Wartelle-Bladou

    Service d'Hépato-Gastroentérologie, Centre Hospitalier du Pays d'Aix, Avenue des tamaris, 13616 Aix-en-Provence cedex 1, France

    1 shared publication

Latest Publications

  • Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study

    by Patrick Marcellin, Michel Chousterman, Thierry Fontanges, Denis Ouzan, Michel Rotily, Marina Varastet, Jean-Philippe Lang, Pascal Melin, Patrice Cacoub, for the CheObs Study Group

    Adherence is important for therapy of chronic diseases, but has still not been well studied in real life in chronic hepatitis C. To assess adherence to hepatitis C combination therapy in routine clinical practice and to identify factors associated with imperfect adherence. This cohort study included unselected chronic hepatitis C patients initiating peginterferon α-2b plus ribavirin. 100% adherence was defined by taking all the prescribed doses of both drugs for the full initially intended duration, as declared by the patient or believed by the physician. Quality of life was assessed using the short-form health survey (SF-36) questionnaire. 1860 patients were analysed, including 72% treatment-naive, 36% genotype 2/3, 23% psychiatric, 44% drug addicts and 3% human immunodeficiency virus (HIV)-positive patients. Early treatment discontinuation occurred in 30% of patients. Overall, 38% of patients reported 100% adherence. Patient- and physician-reported adherences were discordant, with a 20-30% overestimation by physicians. HIV co-infection [odds ratio (OR) 2.52, 95% confidence interval (CI) 1.36-4.67], no drug use during follow-up (2.37, 1.30-4.31), genotype 3 (1.55, 1.20-2.00) and treatment-naive (1.32, 1.03-1.69) were associated with 100% adherence. Quality of life worsened during treatment but returned to baseline after the end of treatment. Imperfect adherence to combination therapy is common in routine patients. Adherence is markedly overestimated by physicians and is associated with some patient's baseline characteristics. Knowledge of these factors might help identify patients who are most in need of intervention and plan more frequent and accurate follow-up.


  • Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study

    by Pascal Melin, Michel Chousterman, Thierry Fontanges, Denis Ouzan, Michel Rotily, Jean-Philippe Lang, Patrick Marcellin, Patrice Cacoub

    Injection drug users are often excluded from hepatitis C virus (HCV) treatment. This study compares sustained virological response, adherence, and quality of life in patients with or without a history of illicit drug use in routine clinical practice. This is a post-hoc analysis of a prospective, observational study conducted in 1860 patients who received peginterferon alpha-2b/ribavirin combination therapy. Nondrug users (NDUs) were defined as patients without a history of drug addiction; former drug users (FDUs) as patients who had stopped using illicit drugs or opioid maintenance therapy and active drug users (ADUs) as patients using illicit drugs or on opioid maintenance therapy. Virological response, adherence, and the health-related quality of life were assessed by the measure of HCV RNA in the serum, self-report and 36-item short-form health survey Questionnaire, respectively. The analyzed population included 1038 (56%) NDUs, 578 (31%) FDUs, and 244 (13%) ADUs. About 85% of ADUs were on opioid maintenance therapy and 25% used illicit drugs. Although ADUs had a more chaotic lifestyle and more psychiatric disorders, sustained virological response of ADUs (58%) did not differ from that of NDUs (49%) and FDUs (51%) (P=0.133). Adherence rates were 39% in NDUs and FDUs, and 37% in ADUs (P=0.883). Health-related quality of life was improved in the three groups after the end of treatment. Our study suggests that HCV therapy in ADUs on opioid maintenance therapy is as effective as in other HCV patients. The effectiveness of HCV therapy in illicit drug users needs to be evaluated in further studies.


    • 30 October 2007
      • Vol. 31, 4S51-5

    [Management of hepatitis C among drug user patients].

    by Joseph Moussalli, Pascal Melin, Claire Wartelle-Bladou, Jean-Philippe Lang

    Opiate substitution treatments radically changed the care management of HCV among drug user patients. Thanks to substitution, it is possible to treat HCV among these patients even with ongoing drug abuse. Overall, in terms of response to treatment, observance, adverse side effects and premature interruptions of treatment, the results are comparable with those observed among non drug addict patients. It is advisable nevertheless to create specific conditions which favour this total care management. The non-invasive fibrosis tests largely improve access to care as compared to liver biopsy. A multidisciplinary team is essential in addressing the associated problem of addiction, hepatitis C and psychiatric co-morbidities. HCV prevails strongly among patients in centres for drug users. These structures are particularly adapted to the management of HCV with the assistance of multidisciplinary teams and access to the non-invasive tests.